
CMPX’s short interest reaches 7.39 million shares on 2025-06-13
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Compass Therapeutics Inc’s recent filing unveils that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Compass Therapeutics
Compass Therapeutics Inc’s recent filing unveils that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0
Compass Therapeutics Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Compass Therapeutics Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on